biostudies-literatureUnknown19(9-10)Le DCPBackground: Heart failure (HF) causes over 266,400 deaths annually. Despite treatment advancements, HF mortality remains high. Induced pluripotent stem cells (iPSCs) offer promising new options. This review assesses iPSC-based treatments for HF.Method: the review included studies from PubMed, ScienceDirect and Web of Science.Results: Analysis of 25 studies with 553 animals showed a baseline ejection fraction (EF) of 39.2 ± 8.9%. iPSC treatment significantly improved EF (MD = 8.6, p < 0.001) and fractional shortening (MD = 6.38, p < 0.001), and reduced ventricular remodeling without increasing arrhythmia risk.Conclusion: iPSC-based therapy improves heart function and reduces ventricular volumes in HF animal models, aligning with promising early clinRegenerative medicine497-509https://www.ebi.ac.uk/biostudies/studies/S-EPMC11487948biostudies-literatureInduced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.PMC11487948Vo QDLe DCPBui HTVu YTHfalseInduced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.Background: Heart failure (HF) causes over 266,400 deaths annually. Despite treatment advancements, HF mortality remains high. Induced pluripotent stem cells (iPSCs) offer promising new options. This review assesses iPSC-based treatments for HF.Method: the review included studies from PubMed, ScienceDirect and Web of Science.Results: Analysis of 25 studies with 553 animals showed a baseline ejection fraction (EF) of 39.2 ± 8.9%. iPSC treatment significantly improved EF (MD = 8.6, p < 0.001) and fractional shortening (MD = 6.38, p < 0.001), and reduced ventricular remodeling without increasing arrhythmia risk.Conclusion: iPSC-based therapy improves heart function and reduces ventricular volumes in HF animal models, aligning with promising early clin2024-01-01T00:00:00Z2024 Sep-Oct2026-06-03T02:28:17.644Z2026-04-23T03:09:54.87ZS-EPMC114879483926395410.1080/17460751.2024.2393558